TABLE 4.
Clinical cure rates and microbiological eradication rates at TOC visit
| Infection | No./total (%)
|
95% CI | P (CMH analysis) | |
|---|---|---|---|---|
| Clinafloxacin | Piperacillin-tazobactam | |||
| Clinical curea | ||||
| All patients | 99/144 (68.8) | 88/135 (65.2) | −7.5%, 14.6% | 0.423 |
| Spontaneous | 44/58 (75.9) | 44/61 (72.1) | ||
| Wound | 40/57 (70.2) | 32/49 (65.3) | ||
| Diabetic foot | 15/29 (51.7) | 12/25 (48.0) | ||
| Microbiological eradication by pathogenb | ||||
| All pathogens | 152/247 (61.5) | 139/243 (57.2) | −4.4%, 13.0% | 0.500 |
| Spontaneous | 48/69 (69.6) | 56/77 (72.7) | ||
| Wound | 72/105 (68.6) | 68/119 (57.1) | ||
| Diabetic foot | 32/73 (43.8) | 15/47 (31.9) | ||
a
Clinically evaluable population. The data are numbers of patients.
b
Microbiologically evaluable population. The data are numbers of isolates.